改进2015年ATA甲状腺乳头状癌复发风险分层的风险预测
基于2539例甲状腺乳头状癌回顾性队列,构建两个预测1年随访时结构不完全反应(SIR)的模型:模型1纳入复发风险分层与淋巴结特征,模型2进一步加入消融前刺激后甲状腺球蛋白(s-Tg)。两模型均优于单纯复发风险分层,模型2在验证队列中保持相似性能。
要点
- 模型1和模型2预测SIR均优于2015年ATA复发风险分层,模型2改善更明显。
- 模型2在独立验证队列中保持相似性能,模型1未显著改善正确重分类。
- 决策曲线显示两模型较风险分层系统在临床决策中提供更大获益。
核心结论
- 纳入淋巴结特征和s-Tg显示出提升现有PTC风险分层系统预测准确性和临床实用性的潜力。
研究设计与样本
- 基于2539例甲状腺乳头状癌患者回顾性队列的全面临床数据,构建两个预测1年随访时结构不完全反应(SIR)的模型。
- 模型1纳入复发风险分层和淋巴结特征(即转移淋巴结数目和比例、N分期)。
- 模型2进一步纳入消融前刺激后甲状腺球蛋白(s-Tg)。
- 使用746例独立队列进行验证分析。
- 采用 integrated discrimination improvement(IDI)和 continuous net reclassification improvement(NRI)评估模型较复发风险分层的预测性能,并用决策曲线分析评估临床效用。
主要发现
- 模型1和模型2预测SIR均优于复发风险分层,正确分类率改善:模型1 IDI=0.02、事件NRI=42.31%,模型2 IDI=0.07、事件NRI=53.54%。
- 决策曲线表明两模型较风险分层系统在临床决策中提供更大获益。
- 验证集中模型2保持相似性能,而模型1未显著改善正确重分类。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Various prognostic factors are expected to refine the American Thyroid Association recurrence risk stratification for patients with papillary thyroid cancer (PTC). However, it remains unclear to what extent integrating these factors improves patient treatment decision-making. METHODS: We developed 2 predictive models for structural incomplete response (SIR) at the 1-year follow-up visit, based on comprehensive clinical data from a retrospective cohort of 2539 patients. Model 1 included the recurrence risk stratification and lymph node features (ie, number and ratio of metastatic lymph nodes, N stage). Model 2 further incorporated preablation stimulated thyroglobulin (s-Tg). An independent cohort of 746 patients was used for validation analysis. We assessed the models' predictive performance compared to the recurrence risk stratification using the integrated discrimination improvement (IDI) and the continuous net reclassification improvement (NRI). The clinical utility of the models was evaluated using decision curve analysis. RESULTS: Both model 1 and model 2 outperformed the recurrence risk stratification in predicting SIR, with improved correct classification rates (model 1: IDI = 0.02, event NRI = 42.31%; model 2: IDI = 0.07, event NRI = 53.54%). The decision curves indicated that both models provided greater benefits over the risk stratification system in clinical decision-making. In the validation set, model 2 maintained similar performance while model 1 did not significantly improve correct reclassification. CONCLUSION: The inclusion of lymph node features and s-Tg showed potential to enhance the predictive accuracy and clinical utility of the existing risk stratification system for PTC patients.
引用
- Wang H, Li Q, Tian T, et al. Improving the Risk Prediction of the 2015 ATA Recurrence Risk Stratification in Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2025. PMID: 38980946. doi:10.1210/clinem/dgae465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。